bioAffinity Statistics
Share Statistics
bioAffinity has 18.25M
shares outstanding. The number of shares has increased by 33.69%
in one year.
| Shares Outstanding | 18.25M |
| Shares Change (YoY) | 33.69% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | n/a |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 943 |
| FTD / Avg. Volume | 0.01% |
Short Selling Information
The latest short interest is 362.57K, so 1.99% of the outstanding
shares have been sold short.
| Short Interest | 362.57K |
| Short % of Shares Out | 1.99% |
| Short % of Float | 2.93% |
| Short Ratio (days to cover) | 1 |
Valuation Ratios
The PE ratio is -1.22 and the forward
PE ratio is -1.01.
bioAffinity's PEG ratio is
0.06.
| PE Ratio | -1.22 |
| Forward PE | -1.01 |
| PS Ratio | 1.18 |
| Forward PS | 0.6 |
| PB Ratio | 4.24 |
| P/FCF Ratio | -1.5 |
| PEG Ratio | 0.06 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for bioAffinity.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.87,
with a Debt / Equity ratio of 0.58.
| Current Ratio | 0.87 |
| Quick Ratio | 0.86 |
| Debt / Equity | 0.58 |
| Debt / EBITDA | -0.18 |
| Debt / FCF | -0.2 |
| Interest Coverage | -96.82 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $164,246 |
| Profits Per Employee | $-158,593.53 |
| Employee Count | 57 |
| Asset Turnover | 1.44 |
| Inventory Turnover | 216.73 |
Taxes
| Income Tax | 11.65K |
| Effective Tax Rate | -0.13% |
Stock Price Statistics
The stock price has increased by -79.91% in the
last 52 weeks. The beta is 3.47, so bioAffinity's
price volatility has been higher than the market average.
| Beta | 3.47 |
| 52-Week Price Change | -79.91% |
| 50-Day Moving Average | 0.48 |
| 200-Day Moving Average | 1.2 |
| Relative Strength Index (RSI) | 47.25 |
| Average Volume (20 Days) | 9,691,975 |
Income Statement
In the last 12 months, bioAffinity had revenue of 9.36M
and earned -9.04M
in profits. Earnings per share was -0.73.
| Revenue | 9.36M |
| Gross Profit | 3.38M |
| Operating Income | -8.95M |
| Net Income | -9.04M |
| EBITDA | -8.33M |
| EBIT | -8.94M |
| Earnings Per Share (EPS) | -0.73 |
Full Income StatementBalance Sheet
The company has 1.11M in cash and 1.5M in
debt, giving a net cash position of -395.9K.
| Cash & Cash Equivalents | 1.11M |
| Total Debt | 1.5M |
| Net Cash | -395.9K |
| Retained Earnings | -53.64M |
| Total Assets | 6.51M |
| Working Capital | -409.81K |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -7.26M
and capital expenditures 0, giving a free cash flow of -7.34M.
| Operating Cash Flow | -7.26M |
| Capital Expenditures | n/a |
| Free Cash Flow | -7.34M |
| FCF Per Share | -0.61 |
Full Cash Flow StatementMargins
Gross margin is 36.09%, with operating and profit margins of -95.64% and -96.56%.
| Gross Margin | 36.09% |
| Operating Margin | -95.64% |
| Pretax Margin | -96.43% |
| Profit Margin | -96.56% |
| EBITDA Margin | -88.98% |
| EBIT Margin | -95.64% |
| FCF Margin | -78.44% |
